Gastric Cancer
A Multicenter, randomized, open label, Phase 3 Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus Trastuzumab plus or minus Pembrolizumab as first line treatment in participants with unresectable, locally advanced or metastatic HER2-postive Gastric or GEJ cancer. (Destiny- Gastric05) (Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus trastuzumab plus or minus Pembrolizumab in first line metastatic HER2-positive gastric or GEJ cancer) (DS8201-724)
- Details
ClinicalTrials.gov ID:
NCT06731478
Diagnosis Type:
NA
USOR Number:
- Address
,
P: